Imatinib Completed Phase 4 Trials for Systemic Mastocytosis Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT01297777Imatinib in KIT-negative Systemic Mastocytosis